Treace Medical Concepts' Fair Value Shifts Down to $4.20, Analysts Maintain Cautious Outlook.

Treace Medical Concepts' fair value has shifted from $4.87 to $4.20, closer to the $3 Street price target, as analysts take a more cautious view of the stock. Stifel has revised its price target from $5 to $3 and maintains a Hold rating, citing concerns about risk and execution. The firm's top ideas in MedTech include Boston Scientific, Edwards Lifesciences, and Solventum, which may serve as a reference point for Treace Medical Concepts' performance.